Adjusted changes from baseline in DXA-derived body composition measures during the main period (left hand graphs) and extension period (right hand graphs) (full analysis set). ETD values are shown for somapacitan minus placebo (main period) and for somapacitan/somapacitan minus daily GH/daily GH (extension period). For effects on fat mass, a reduction is desired. A negative ETD means the reduction appeared more pronounced with somapacitan than with the comparator. For effects on lean mass, an increase is desired. A positive ETD means the increase appeared more pronounced with somapacitan than with the comparator. Adjusted values are change from baseline estimates based on an analysis of covariance model (main period) or mixed model for repeated measurements (extension period) adjusted for baseline characteristics. The y-axes show the adjusted change from baseline at week 34 or week 86. Abbreviations: CI, confidence interval; DXA, dual-energy x-ray absorptiometry; ETD, estimated treatment difference; GH, growth hormone; soma, sompacitan.